Newsroom

Sorted by: Latest

-

東京海上日動あんしん生命保険株式会社と2回目のアセット・インテンシブ再保険契約を発表

日本--(BUSINESS WIRE)--(ビジネスワイヤ) -- グローバルな再保険業界のリーディングプレイヤーであるPacific Life Reは、東京海上日動あんしん生命保険株式会社(以下「あんしん生命」)との2回目となる共同保険式再保険の契約を本日発表しました。 本契約は個人終身保険契約ブロックを受再する再保険契約であり、2024年の取引実績を踏まえた上で、あんしん生命の長期金利リスクを軽減する手法を提供するとともに、同社の資産と負債のリスク管理の高度化に貢献します。 「あんしん生命との本取引を発表できることを、大変喜ばしく思います。日本における共同保険式再保険の提供は、当社のコア・ビジネス戦略の策定において重要な役割を果たします。当社があんしん生命の個人終身保険契約ブロックを受再することで、契約ポートフォリオの資本をより効率的に最適化し、事業目標の達成や資本管理に必要な長期的なサポートをご提供して参ります。」 Pacific Life ReのSavings&Retirement部門 エグゼクティブ・バイス・プレジデント、フィル・ビーチは述べました。 Pacific Lif...
-

Kirby McInerney LLP Reminds Ibotta, Inc. (IBTA) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors who purchased Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE:IBTA) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [CONTACT FORM] The lawsuit was filed on behalf of investors who acquired Ibotta securities in connect...
-

The Cannabist Company Announces Receipt of Court Approval of Previously Announced Plan of Arrangement

CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today provided an update in respect of the previously announced plan of arrangement under Section 192 of the Canada Business Corporations Act (the “Arrangement”) involving the Company, The Cannabist Company Holdings (Canada) Inc. and 16834434 Canada...
-

HSON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Hudson Global, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Hudson Global, Inc. (NASDAQ: HSON) and Star Equity Holdings, Inc. is fair to Hudson shareholders. Upon completion of the proposed transaction, Hudson shareholders will own approximately 79% of the combined company. Halper Sadeh encourages Hudson shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or...
-

CCM Biosciences anuncia la presentación de los datos de su primer fármaco de su clase contra el CPNM en ASCO 2025

MOUNT LAUREL, Nueva Jersey--(BUSINESS WIRE)--CCM Biosciences, empresa diversificada dedicada al descubrimiento y desarrollo farmacéutico, anuncia la próxima presentación de su programa de fármacos inhibidores del EGFR de 4.ª generación para el cáncer de pulmón no microcítico (CPNM) en la 2025 Conferencia Anual de la Sociedad Americana de Oncología Clínica (ASCO), que tendrá lugar del 30 de mayo al 3 de junio en Chicago. El CPNM, que representa el 80% de los cánceres de pulmón, es la causa más f...
-

STRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Star Equity Holdings, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Star Equity Holdings, Inc. (NASDAQ: STRR) to Hudson Global, Inc. is fair to Star shareholders. Upon completion of the proposed transaction, Star shareholders will own approximately 21% of the combined company. Halper Sadeh encourages Star shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ha...
-

Riassunto: CCM Biosciences annuncia la presentazione all'ASCO 2025 di dati del programma incentrato sul suo farmaco first in class per il trattamento del NSCLC

MOUNT LAUREL, N.J.--(BUSINESS WIRE)--CCM Biosciences, azienda diversificata di ricerca e sviluppo farmaceutico, oggi ha annunciato la prossima presentazione alla conferenza annuale 2025 dell'American Society of Clinical Oncology (ASCO), in programma a Chicago dal 30 maggio al 3 giugno, del suo programma di farmaci inibitori dell'EGFR di quarta generazione contro il carcinoma polmonare non a piccole cellule (NSCLC). Il NSCLC, che costituisce l'80% dei carcinomi polmonari, rappresenta la causa pi...
-

CCM Biosciences 宣佈將於 ASCO 2025 發佈其首創 NSCLC 藥物項目數據

勞雷爾山,新澤西州--(BUSINESS WIRE)--(美國商業資訊)-- CCM Biosciences 作為一間多元化的藥物研發公司,今日宣佈將於 2025 年 5 月 30 日至 6 月 3 日於芝加哥舉行的美國臨床腫瘤學會 (ASCO) 2025 年會上,發佈其針對非小細胞肺癌(NSCLC)的第四代 EGFR 抑制劑研發項目。 NSCLC 佔肺癌病例的 80%,是全球最常見的癌症致死原因。表皮生長因子受體(EGFR)激活性突變(如 Del19 或 L858R)是 NSCLC 的主要致癌驅動因素。EGFR 陽性 NSCLC 約佔所有診斷病例的 30%,與 PD-L1 陽性 NSCLC 市場規模相近(後者是目前全球最暢銷藥物 Keytruda® 的治療對象)。目前 EGFR 陽性 NSCLC 的標準治療方案是第三代 抑制劑,其中最著名的是奧希替尼 (Osimertinib,商品名:Tagrisso®),其年銷售額超過 60億美元。大多數接受酪氨酸激酶抑制劑 (TKIs) 治療的患者最終會產生耐藥性突變,包括 T790M gatekeeper 突變。作為第三代共價 TKI,奧希替尼...
-

American Lending Center Continues Fast Pace Of I-956F Project Approvals

IRVINE, Calif.--(BUSINESS WIRE)--American Lending Center (ALC) recently received I-956F approval for another EB-5 project, its 29th straight federal approval since the Reform and Integrity Act (RIA) passed in March 2022. This is a record for that industry. In the last three years, ALC has successfully financed 31 EB-5 projects in 17 different states and 11 different industries, ranging from commercial real estate to vertical farming to clean energy to hospital/medical facilities. Each of these...
-

Přední středovýchodní společnost v oblasti umělé inteligence TII uvádí na trh dva nové modely umělé inteligence: Falcon Arabic – první arabský model řady Falcon – a Falcon-H1, nejvýkonnější model ve své třídě.

ABÚ ZABÍ, Spojené arabské emiráty--(BUSINESS WIRE)--Technologický inovační institut Spojených arabských emirátů (TII), aplikovaná výzkumná organizace Rady pro pokročilé technologie v Abú Zabí (ATRC), dnes představil dvě významné novinky v oblasti umělé inteligence: Falcon Arabic, vůbec první arabský jazykový model v řadě Falcon, který je nyní nejvýkonnějším arabským modelem umělé inteligence v regionu, a Falcon-H1, nový model, který díky nové architektuře přináší nový rozměr výkonu a přenositel...